Why CanniMed Therapeutics Inc. Soared 17.18% on Thursday

CanniMed Therapeutics Inc. (TSX:CMED) soared 17.18% on Thursday after announcing that it will discuss a possible deal with Aurora Cannabis Inc. (TSX:ACB). What should you do now?

| More on:

What?

Canadian medical cannabis producer CanniMed Therapeutics Inc. (TSX:CMED) watched its stock roar 17.18% higher in Thursday’s trading session following its announcement that it has postponed its special shareholders’ meeting to vote on its proposed takeover of Newstrike Resources Ltd. (TSXV:HIP) in order to discuss a possible transaction with Aurora Cannabis Inc. (TSX:ACB).

So what?

Aurora had originally tried to acquire CanniMed in November, but CanniMed was not a fan of the deal and has done everything in its power to prevent it, including launching its takeover of Newstrike Resources and filing a $725 million lawsuit against Aurora, but it seems like the two sides are finally on speaking terms and will meet to discuss a potential deal.

Aurora has been accumulating shares of CanniMed since announcing its intention to take the company over on November 24, with its most recent press release showing an aggregate number of shares purchased at 700,600, which have a market value of approximately $22.84 million at the close of trading on Thursday, but it has agreed to not acquire any additional shares during the standstill period that will last until January 21 at 11:59 P.M. (EST).

Now what?

Cannabis is right up there with cryptocurrency and blockchain technology as one of the most-talked-about topics in the investment world today, especially in Canada, and it has been one of the most active in terms of deal making as well. I think a deal between CanniMed and Aurora would make the combined company an absolute powerhouse in the industry with far greater long-term growth potential, and it would give it elite status alongside Canopy Growth Corp. and Aphria Inc. in my mind, so I am definitely rooting for the deal to get done. 

With all of this being said, I would avoid making new investments in CanniMed or Aurora until we know more about the possible deal on January 21, so stay tuned!

Fool contributor Joseph Solitro has no position in any stocks mentioned.

More on Investing

staying calm in uncertain times and volatility
Dividend Stocks

1 Top Dividend Stock to Buy and Hold for 10 Years

A dividend stock with stable earnings and growing dividends is a top buy-and-hold candidate for long-term investors.

Read more »

dividend stocks are a good way to earn passive income
Dividend Stocks

Here’s How to Turn $25,000 Into TFSA Cash Flow

Got $25,000 in your TFSA? Here's how investing in Enbridge stock at a 5.2% yield can turn that lump sum…

Read more »

pig shows concept of sustainable investing
Investing

2 Exceptional Stocks for Your $7,000 TFSA Contribution in 2026

Given their low-risk business models and visible growth prospects, these two Canadian stocks are ideal additions to your TFSA right…

Read more »

3 colorful arrows racing straight up on a black background.
Energy Stocks

3 Stocks to Buy and Hold for 2026 and Beyond

Three TSX stocks are buy-and-hold candidates for 2026 and beyond for dividend sustainability and pricing power.

Read more »

ETFs can contain investments such as stocks
Investing

Why I Keep Adding to This ETF and Never Plan to Stop

ALLW is why I sleep well at night despite all the risks out there for my investments.

Read more »

woman considering the future
Dividend Stocks

3 Dividend Stocks Worth Doubling Down on Right Now

With a clear growth strategy and consistent execution, these three Canadian dividend stocks continue to build momentum.

Read more »

dividend stocks are a good way to earn passive income
Dividend Stocks

My 3 Favourite Stocks for Monthly Passive Income

Do you want to get a monthly passive-income boost? Check out these three dividend stocks with growing businesses and rising…

Read more »

stocks climbing green bull market
Investing

These 3 Canadian Stocks Could Triple in 5 Years

These three Canadian growth stocks have massive growth potential and trade at compelling valuations, making them some of the best…

Read more »